| Home > Publications database > Structural elucidation and antiviral activity of covalent cathepsin L inhibitors |
| Typ | Amount | VAT | Currency | Share | Status | Cost centre |
| Hybrid-OA | 0.00 | 0.00 | EUR | (Publish and Read) | 810 / 476152 | |
| Hybrid-OA | -700.00 | 0.00 | EUR | (Storniert) | 810 / 476152 | |
| Hybrid-OA | 700.00 | 0.00 | EUR | (Zahlung erfolgt) | 28901 / 476152 | |
| Sum | 0.00 | 0.00 | EUR | |||
| Total | 0.00 |
| Journal Article | PUBDB-2024-00424 |
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ;
2024
ACS
Washington, DC
This record in other databases:
Please use a persistent id in citations: doi:10.1021/acs.jmedchem.3c02351 doi:10.3204/PUBDB-2024-00424
Abstract: Emerging RNA viruses, including SARS-CoV-2, continue to be a major threat. Cell entry of SARS-CoV-2 particles via the endosomal pathway involves cysteine cathepsins. Due to ubiquitous expression, cathepsin L (CatL) is considered a promising drug target in the context of different viral and lysosome-related diseases. We characterized the anti-SARS-CoV-2 activity of a set of carbonyl- and succinyl epoxide-based inhibitors, which were previously identified as inhibitors of cathepsins or related cysteine proteases. Calpain inhibitor XII, MG-101, and CatL inhibitor IV possess antiviral activity in the very low nanomolar EC50 range in Vero E6 cells and inhibit CatL in the picomolar Ki range. We show a relevant off-target effect of CatL inhibition by the coronavirus main protease α-ketoamide inhibitor 13b. Crystal structures of CatL in complex with 14 compounds at resolutions better than 2 Å present a solid basis for structure-guided understanding and optimization of CatL inhibitors toward protease drug development.
|
The record appears in these collections: |